Haleon Plc - ADR [HLN] vs Neurocrine [NBIX] Detailed Stock Comparison
Haleon Plc - ADR
NYSE
Loading...
Neurocrine
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Haleon Plc - ADR wins in 8 metrics, Neurocrine wins in 11 metrics, with 0 ties. Neurocrine appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Haleon Plc - ADR | Neurocrine | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 21.44 | 38.94 | Haleon Plc - ADR |
| Price-to-Book Ratio | 5.44 | 4.84 | Neurocrine |
| Debt-to-Equity Ratio | 53.41 | 18.18 | Neurocrine |
| PEG Ratio | 22.98 | 21.19 | Neurocrine |
| EV/EBITDA | 36.05 | 23.82 | Neurocrine |
| Profit Margin (TTM) | 13.81% | 13.88% | Neurocrine |
| Operating Margin (TTM) | 22.21% | 21.18% | Haleon Plc - ADR |
| EBITDA Margin (TTM) | 22.21% | 21.18% | Haleon Plc - ADR |
| Return on Equity | 9.38% | 13.39% | Neurocrine |
| Return on Assets (TTM) | 4.61% | 8.67% | Neurocrine |
| Free Cash Flow (TTM) | $1.98B | $557.20M | Haleon Plc - ADR |
| Dividend Yield | 1.63% | N/A | N/A |
| 1-Year Return | -0.31% | -8.35% | Haleon Plc - ADR |
| Price-to-Sales Ratio (TTM) | 3.96 | 5.20 | Haleon Plc - ADR |
| Enterprise Value | $128.31B | $12.57B | Haleon Plc - ADR |
| EV/Revenue Ratio | 8.59 | 5.01 | Neurocrine |
| Gross Profit Margin (TTM) | 55.38% | 98.36% | Neurocrine |
| Revenue per Share (TTM) | $2 | $25 | Neurocrine |
| Earnings per Share (Diluted) | $0.45 | $3.38 | Neurocrine |
| Beta (Stock Volatility) | 0.24 | 0.25 | Haleon Plc - ADR |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Haleon Plc - ADR vs Neurocrine Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Haleon Plc - ADR | -0.52% | 1.15% | -0.82% | -9.56% | -3.40% | 2.22% |
| Neurocrine | 1.21% | 6.31% | 1.26% | 10.50% | 16.61% | -3.60% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Haleon Plc - ADR | -0.31% | 61.37% | 30.23% | 30.23% | 30.23% | 30.23% |
| Neurocrine | -8.35% | 24.21% | 17.50% | 203.77% | 2,152.54% | 182.11% |
Performance & Financial Health Analysis: Haleon Plc - ADR vs Neurocrine
| Metric | HLN | NBIX |
|---|---|---|
| Market Information | ||
| Market Cap | $43.62B | $13.05B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 8,838,500 | 1,278,970 |
| 90 Day Avg. Volume | 11,194,110 | 982,507 |
| Last Close | $9.65 | $132.90 |
| 52 Week Range | $8.86 - $11.42 | $84.23 - $154.87 |
| % from 52W High | -15.50% | -14.19% |
| All-Time High | $11.42 (Jun 02, 2025) | $157.98 (Jul 29, 2024) |
| % from All-Time High | -15.50% | -15.88% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.01% | 0.17% |
| Quarterly Earnings Growth | 0.33% | 0.65% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.14% |
| Operating Margin (TTM) | 0.22% | 0.21% |
| Return on Equity (TTM) | 0.09% | 0.13% |
| Debt to Equity (MRQ) | 53.41 | 18.18 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.77 | $27.22 |
| Cash per Share (MRQ) | $0.08 | $9.84 |
| Operating Cash Flow (TTM) | $3.37B | $567.30M |
| Levered Free Cash Flow (TTM) | $2.61B | $367.04M |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.63% | N/A |
| Last 12-Month Dividend | $0.17 | N/A |
Valuation & Enterprise Metrics Analysis: Haleon Plc - ADR vs Neurocrine
| Metric | HLN | NBIX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 21.44 | 38.94 |
| Forward P/E | 22.98 | 21.19 |
| PEG Ratio | 22.98 | 21.19 |
| Price to Sales (TTM) | 3.96 | 5.20 |
| Price to Book (MRQ) | 5.44 | 4.84 |
| Market Capitalization | ||
| Market Capitalization | $43.62B | $13.05B |
| Enterprise Value | $128.31B | $12.57B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.59 | 5.01 |
| Enterprise to EBITDA | 36.05 | 23.82 |
| Risk & Other Metrics | ||
| Beta | 0.24 | 0.25 |
| Book Value per Share (MRQ) | $1.77 | $27.22 |
Financial Statements Comparison: Haleon Plc - ADR vs Neurocrine
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HLN | NBIX |
|---|---|---|
| Revenue/Sales | $2.76B | $572.60M |
| Cost of Goods Sold | $1.23B | $9.20M |
| Gross Profit | $1.53B | $563.40M |
| Research & Development | $78.00M | $263.20M |
| Operating Income (EBIT) | $350.00M | $23.70M |
| EBITDA | $362.00M | $40.30M |
| Pre-Tax Income | $288.00M | $14.70M |
| Income Tax | $66.00M | $6.80M |
| Net Income (Profit) | $222.00M | $7.90M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HLN | NBIX |
|---|---|---|
| Cash & Equivalents | $2.20B | $194.10M |
| Total Current Assets | $5.72B | $1.64B |
| Total Current Liabilities | $5.81B | $522.90M |
| Long-Term Debt | $8.62B | $447.50M |
| Total Shareholders Equity | $16.22B | $2.54B |
| Retained Earnings | $27.27B | $-5.30M |
| Property, Plant & Equipment | $0 | $589.20M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HLN | NBIX |
|---|---|---|
| Operating Cash Flow | N/A | $21.80M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | $54.10M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-150.00M |
Short Interest & Institutional Ownership Analysis
| Metric | HLN | NBIX |
|---|---|---|
| Shares Short | 17.45M | 2.85M |
| Short Ratio | 1.39 | 3.10 |
| Short % of Float | 0.00% | 0.04% |
| Average Daily Volume (10 Day) | 8,838,500 | 1,278,970 |
| Average Daily Volume (90 Day) | 11,194,110 | 982,507 |
| Shares Outstanding | 12.36B | 99.40M |
| Float Shares | 8.95B | 98.00M |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 0.13% | 0.98% |
Dividend Analysis & Yield Comparison: Haleon Plc - ADR vs Neurocrine
| Metric | HLN | NBIX |
|---|---|---|
| Last 12-Month Dividend | $0.17 | N/A |
| Last 12-Month Dividend Yield | 1.63% | N/A |
| 3-Year Avg Annual Dividend | $0.11 | N/A |
| 3-Year Avg Dividend Yield | 0.91% | N/A |
| 3-Year Total Dividends | $0.34 | N/A |
| Ex-Dividend Date | Apr 25, 2025 | N/A |